Randomized Phase II Trial of Chemotherapy of Physician's Choice Plus Trastuzumab Versus Chemotherapy of Physician's Choice Plus Trastuzumab Plus Pertuzumab In Women With Pretreated, HER2-Overexpressing Metastatic Breast Cancer (MBC)
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Oct 2018
Price : $35 *
At a glance
- Drugs Pertuzumab (Primary) ; Capecitabine; Docetaxel; Paclitaxel; Trastuzumab; Vinorelbine
- Indications Breast cancer
- Focus Therapeutic Use
- Sponsors US Oncology Research
- 27 Sep 2018 Planned End Date changed from 1 Feb 2018 to 31 Dec 2019.
- 27 Sep 2018 Planned primary completion date changed from 1 Feb 2018 to 31 Dec 2019.
- 31 Aug 2018 Biomarkers information updated